John C. Martin

This profile gathers the share dealings of John C. Martin across 4 companies, led by Gilead Sciences, Inc., Gen Probe Inc and Kronos Bio, Inc. In total, 669 filings cover trades dated from 16 February 2006 to 3 March 2021.

Both buying and selling appear: 2 purchases worth €1.5M, against 434 sales worth €857.2M. On balance, insiders were net sellers of €855.7M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 61 share grants and 157 option exercises.

Most recently, on 5 March 2021, the filings show a share grant in Sarepta Therapeutics, Inc. The last insider purchase was made public on 16 October 2020, 2,214 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.